After several years of collaboration, Professor Dr Dean Lee has become a formal member of the scientific advisory board of CiMaas as of December 18, 2022.
Dean Lee is a physician in the Division of Hematology and Oncology at Nationwide Children’s Hospital and director of the Cellular Therapy and Cancer Immunology Program at Nationwide Children’s Hospital and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. He is a professor of pediatrics at The Ohio State University College of Medicine and the DiMarco Family Endowed Chair in Cell Based Therapy.
Dr. Lee earned his bachelor’s degree in natural sciences from Fresno Pacific College, completed his medical, doctoral, and pediatric residency training at Loma Linda University then completed a fellowship in pediatric hematology/oncology at Texas Children’s Hospital, Baylor College of Medicine. Dr. Lee is chair of the Cellular Therapy Strategy Group for the Pediatric Blood and Marrow Transplant Consortium, member of the NIH Recombinant DNA Advisory Committee, and member of the Cell Therapy Steering Committee for the Children’s Oncology Group.
His research centers around translational and early-phase clinical research of cellular therapy for pediatric cancers. He developed a method for generating donor NK cells for use in adoptive immunotherapy which enables large-scale expansion of NK cells from peripheral blood of normal donors, patients, cord blood, and iPSC/hESC without replicative senescence. Primary NK cells have been infused into more than 80 patients. His research has earned patents and commercial licenses in the field of cellular therapy.
Dr. Lee practices clinically in bone marrow transplantation, with an interest in haplotransplantation and graft engineering for myeloid malignancies.adoptive cell therapy, advisory board, NK cells